21
Dosing Frequency Comments
†
Once daily • Oral agents
• CVOTs show no reduction in cardiovascular events when
added to statin therapy in individuals being treated for
secondary prevention of ASCVD
• Last-line agent for severe hypertriglyceridemia due to relatively
high risk of intolerable side effects; must initiate low dose to
minimize side effects and slowly titrate up to an effective dose
• Expected TG reduction: sustained-release, 10%–30%;
immediate-release 20%–50%
‡
• Increases insulin resistance, high rates of skin flushing, and
significant hepatotoxicity
Twice to 3
times daily
Once monthly • Subcutaneous agent
• Only approved for familial chylomicronemia syndrome
• Expected TG reduction in familial chylomicronemia
syndrome: 30% (placebo-corrected is 42.5%)
‡
